Meeting NewsVideo

VIDEO: RET inhibitor shows promise in advanced NSCLC

CHICAGO — At the ASCO Annual Meeting, HemOnc Today Next Gen Innovator Yanis Boumber, MD, PhD, assistant professor in thoracic medical oncology at Fox Chase Cancer Center, reviews the safety and efficacy of BLU-667, an investigational RET inhibitor.

Findings from the ARROW trial showed BLU-667 (Blueprint Medicines) was well tolerated and demonstrated potent and durable antitumor activity in patients with RET-fusion-positive advanced NSCLC.

“I think this new drug is highly promising as a breakthrough drug [and] as a new option for patients with RET-positive NSCLC,” Boumber told HemOnc Today.

Reference:

Gainor JF, et al. Abstract 9008. Presented at: ASCO Annual Meeting; May 31- June 4, 2019; Chicago.

Disclosure: Boumber reports serving on advisory boards for AbbVie, AstraZeneca and Caris Life Sciences, Inc.

CHICAGO — At the ASCO Annual Meeting, HemOnc Today Next Gen Innovator Yanis Boumber, MD, PhD, assistant professor in thoracic medical oncology at Fox Chase Cancer Center, reviews the safety and efficacy of BLU-667, an investigational RET inhibitor.

Findings from the ARROW trial showed BLU-667 (Blueprint Medicines) was well tolerated and demonstrated potent and durable antitumor activity in patients with RET-fusion-positive advanced NSCLC.

“I think this new drug is highly promising as a breakthrough drug [and] as a new option for patients with RET-positive NSCLC,” Boumber told HemOnc Today.

Reference:

Gainor JF, et al. Abstract 9008. Presented at: ASCO Annual Meeting; May 31- June 4, 2019; Chicago.

Disclosure: Boumber reports serving on advisory boards for AbbVie, AstraZeneca and Caris Life Sciences, Inc.

    See more from Discoveries from ASCO: Lung Cancer